Acorda's GGF2 in Another Study - Analyst Blog

By
A A A

Acorda Therapeutics, Inc. ( ACOR ) continues to progress with its pipeline with the company enrolling the first patient in a phase Ib single-infusion study being conducted with glial growth factor 2 (GGF2). The study is being conducted in patients with heart failure. Three doses of GGF2 will be evaluated along with efficacy outcomes.

Acorda has been looking to expand its pipeline and reduce its dependence on lead product, Ampyra, which is approved for the improvement of walking in multiple sclerosis patients. Apart from studying Ampyra for additional indications like cerebral palsy and post-stroke deficits (phase IIb/III study to commence in the second quarter of 2014), Acorda is evaluating other candidates like rHIgM22 (multiple sclerosis - phase I ongoing) and AC105.

In late Sep 2013, Acorda started enrolling patients in a phase II study being conducted with AC105. The double-blind, randomized, placebo controlled study is being conducted in patients with traumatic spinal cord injury (SCI). AC105's safety and efficacy will be evaluated in this study which will have many exploratory efficacy measures.

Acorda is also looking towards in-licensing deals and acquisitions to expand its pipeline. In Dec 2012, Acorda acquired Neuronex and added diazepam nasal spray (management of seizure in certain epilepsy patients) to its pipeline. Further, in Jul 2013, Acorda acquired NGX-1998, a phase III ready product for treating patients suffering neuropathic pain, and Quenteza, an approved product for the treatment of postherpetic neuralgia.

Acorda currently carries a Zacks Rank #3 (Hold). At present, companies like Actelion Ltd. ( ALIOF ), Isis Pharmaceuticals ( ISIS ) and Agenus Inc. ( AGEN ) look attractive. While Actelion and Isis Pharma are Zacks Rank #1 (Strong Buy) stocks, Agenus is a Zacks Rank #2 (Buy) stock.



ACORDA THERAPT (ACOR): Free Stock Analysis Report

AGENUS INC (AGEN): Free Stock Analysis Report

ACTELION LTD (ALIOF): Get Free Report

ISIS PHARMACEUT (ISIS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ACOR , AGEN , ALIOF , ISIS , SCI

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

37,246,891
  • $42.6299 ▲ 1.29%
24,793,842
  • $47.0355 ▲ 0.76%
23,736,028
  • $5.11 ▼ 5.55%
22,633,601
  • $17.0601 ▲ 0.12%
19,912,047
  • $101.70 ▼ 0.09%
17,687,515
  • $39.835 ▼ 4.13%
16,702,927
  • $34.984 ▼ 0.53%
14,143,927
  • $25.265 ▲ 0.18%
As of 9/19/2014, 10:13 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com